OTCMKTS:GOVX - Geovax Labs Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0280 0.00 (0.00 %)
(As of 12/12/2018 03:27 AM ET)
Previous Close$0.0280
Today's Range$0.0278 - $0.0290
52-Week Range$0.0175 - $0.06
Volume254,167 shs
Average Volume830,321 shs
Market Capitalization$6.35 million
P/E Ratio-0.93
Dividend YieldN/A
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; and CaroGen Corporation. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Commercial physical research
Current SymbolOTCMKTS:GOVX
Previous SymbolNASDAQ:GOVX


Debt-to-Equity RatioN/A
Current Ratio0.45
Quick Ratio0.45


Trailing P/E Ratio-0.93
Forward P/E Ratio-1.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.08 million
Price / Sales5.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.02) per share
Price / Book-1.40


EPS (Most Recent Fiscal Year)($0.03)
Net Income$-2,170,000.00
Net Margins-290.02%
Return on EquityN/A
Return on Assets-422.86%


Outstanding Shares218,900,000
Market Cap$6.35 million
OptionableNot Optionable

Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) announced its quarterly earnings data on Thursday, May, 3rd. The biotechnology company reported ($0.01) earnings per share for the quarter. The biotechnology company had revenue of $0.22 million for the quarter. View Geovax Labs' Earnings History.

When is Geovax Labs' next earnings date?

Geovax Labs is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for Geovax Labs.

Has Geovax Labs been receiving favorable news coverage?

News articles about GOVX stock have trended somewhat positive on Wednesday, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Geovax Labs earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Geovax Labs' key competitors?

Who are Geovax Labs' key executives?

Geovax Labs' management team includes the folowing people:
  • Mr. David Alan Dodd, Chairman, CEO & Pres (Age 68)
  • Dr. Harriet Latham Robinson, Co-Founder, Chief Scientific Officer Emeritus & Director (Age 80)
  • Mr. Mark W. Reynolds CPA, CPA, CFO & Corp. Sec. (Age 56)
  • Dr. Farshad Guirakhoo, Chief Scientific Officer (Age 65)
  • Mr. Donald G. Hildebrand, Founder, Chairman Emeritus & Consultant (Age 77)

How do I buy shares of Geovax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geovax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $0.0280.

How big of a company is Geovax Labs?

Geovax Labs has a market capitalization of $6.35 million and generates $1.08 million in revenue each year. The biotechnology company earns $-2,170,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. Geovax Labs employs 9 workers across the globe.

What is Geovax Labs' official website?

The official website for Geovax Labs is http://www.geovax.com.

How can I contact Geovax Labs?

Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]

MarketBeat Community Rating for Geovax Labs (OTCMKTS GOVX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about Geovax Labs and other stocks. Vote "Outperform" if you believe GOVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel